Oral anticoagulant rivaroxaban (brand name Xarelto), a popular blood thinner prescribed after a person suffers a blood clot or is diagnosed with atrial fibrillation, has a higher risk of bleeding complications than several other medications on the market, a new study reports.
The findings of the study, conducted by a team at the University of Michigan Medical School, were reported at the 2023 American Society of Hematology’s Annual Meeting & Exposition.
